IFNB1 and myeloid sarcoma: Patients with MS require long-term disease-modifying therapy (DMT) to help regulate their disease progression and reduce relapse rates; DMT may impact the risk profile of MS patients, while interferon beta therapy is associated with a lower risk of infection [11,12].